Last reviewed · How we verify
intraarticular injection
intraarticular injection is a Small molecule drug developed by Federal University of São Paulo. It is currently in Phase 2 development. Also known as: Triancil®, Theracort®, arthrocentesis.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | intraarticular injection |
|---|---|
| Also known as | Triancil®, Theracort®, arthrocentesis |
| Sponsor | Federal University of São Paulo |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Arthralgia
- Procedural pain
- Headache
- Back pain
- Nasopharyngitis
- Upper respiratory tract infection
- Osteoarthritis
- Urinary tract infection
- Joint swelling
- Musculoskeletal pain
- Bronchitis
- Hypertension
Key clinical trials
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- OMT for Adhesive Capsulitis (PHASE4)
- Arthrosemid vs. Steroid for the Management Knee Osteoarthritis (PHASE4)
- The Effectiveness of BETY in Knee Osteoarthritis With Intra-Articular Injections (NA)
- A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis. (PHASE1, PHASE2)
- Capsular Distension Versus Corticosteroid Injection in Adhesive Capsulitis (NA)
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intraarticular injection CI brief — competitive landscape report
- intraarticular injection updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI
Frequently asked questions about intraarticular injection
What is intraarticular injection?
Who makes intraarticular injection?
Is intraarticular injection also known as anything else?
What development phase is intraarticular injection in?
What are the side effects of intraarticular injection?
Related
- Manufacturer: Federal University of São Paulo — full pipeline
- Also known as: Triancil®, Theracort®, arthrocentesis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing